PIERIS PHARMACEUT. DL-001 WKN: A12G4Q ISIN: US7207951036 Forum: Aktien Thema: Hauptdiskussion

📍

Huch kurzzeitig Raketen Männer waren auch hier 😂😂😂😂 Wenn das los geht kommt de Satz: „Keiner hat das Ding auf dem Schirm!“ 😂😂😂😂😂😂😂😂

👀

Beobachten

Läuft

Volumen ist immer noch guter Durchschnitt… spannend wird die $6 Marke… nach wie vor bemerkenswert - jeder dip wir little by little aufgefressen…

Grün: 0,18 - Vol. 1,18 Mio

Pieris Pharmaceuticals Inc.: The Winning Streak Continues (PIRS) (MENAFN - Investor Brand Network) Pieris Pharmaceuticals Inc. (NASDAQ:PIRS) traded at a new 52-week high today of $5.82. This new high was reached on above average trading volume as 29.7 million shares traded hands, while the average 30-day volume is approximately 1.4 million shares. In the past 52 weeks, shares of Pieris Pharmaceuticals Inc. have traded between a low of $1.70 and a high of $5.82 and is now at $5.69, which is 235% above that low price. Pieris Pharmaceuticals Inc. (NASDAQ:PIRS) is currently priced 25.9% above its average consensus analyst price target of $4.22.

Volumen: 3,76 Mio (Avrg: 3,04)

Grün: 8,99%

👀

Pieris Pharmaceuticals to Participate in Upcoming Investor Conferences Thu, September 9, 2021, 2:00 PM BOSTON,MA / ACCESSWIRE / September 9,2021 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer, and other indications, today announced that members of the management team will participate in the following upcoming investor conferences:

Grün 0,58

he 5 contracts listed below are agreements signed since Covid, There may be other these are the ones I know of. Collaboration with a) AstraZeneca : AstraZeneca has paid $45 million and committed to up to $2.1 billion in milestones to team with Pieris Pharmaceuticals. The agreement sets Pieris up to move respiratory candidate PRS-060 into the clinic on AstraZeneca’s dime and pull in milestones as it and other pipeline prospects advance. with b) Genentech : $20 million upfront up to $1.4B potential payment royalties in milestones across multiple platforms with c) SeaGen: $13 million investment at 3.51 per share $1.2B potential payment royalties with d) Boston Pharma : 10 million upfront potential $353M payment royalties and undisclosed amount for manufacturing, yahoo board says this is not $800 million now I can't find any press release where this changed wtih e) Lilly - clinical trial collaboration and supply agreement to evaluate a combination of candidates in multiple types of solid tumoirs, including HER2-positive tumours. The clinical trial programme will evaluate the safety and efficacy of Pieris’ PRS-343, a 4-1BB/HER2 bispecific targeting HER2-positive tumours

Rot -1,7

Rot -1,31